A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct Treatment in Patients With Borderline Personality Disorder

What this Trial Is About

Borderline Personality Disorder (BPD) is a common and serious psychiatric condition that affects millions worldwide, leading to significant difficulties in daily life and high rates of suicidal thoughts and actions. Young women are especially at risk, with BPD being diagnosed three times more often in women than men. The causes of BPD are complex, involving both biological and environmental factors such as abuse and family issues, which contribute to emotional and behavioral challenges. Currently, no medications are specifically approved to treat BPD effectively, and many patients struggle with existing treatments due to side effects or lack of response. Researchers are evaluating a novel drug that blocks a brain receptor called NMDA, which has been approved for Alzheimer's disease and is being studied for other psychiatric conditions. In this trial, 150 adults with BPD will be randomly assigned to receive either the study drug at a dose of 20 mg daily or a placebo, in addition to their current antipsychotic treatment, for 12 weeks. The trial is double-blind, meaning neither participants nor researchers know who receives the drug or placebo, to fairly assess the drug's effects. Participants will be closely monitored throughout the study with regular assessments of their borderline symptoms and cognitive function using specific rating scales at multiple time points over 12 weeks. Safety and tolerability will also be observed. This thorough evaluation aims to determine whether adding this novel drug can improve symptoms and functioning in people living with BPD during and at the end of the treatment period.

A Novel Drug for Borderline Personality Disorder